The Aurora family of serine/threonine kinases has an important role in chromosome alignment, segregation and cytokinesis during mitosis. The Aurora family consists of three members: Aurora A, B and C, which share 67-76% amino acid sequence identity in their catalytic domains, and few similarities in their N-terminus.
1,2 Aurora A localizes on centrosomes and has a crucial role in each step of mitosis including bipolar spindle formation. 2 Aurora B is a chromosomal passenger protein and localizes at centromeres during prometaphase and subsequently relocates to midzone microtubules and midbodies during anaphase and telophase. 1, 3 Aurora B has a role in chromosome alignment, kinetochore-microtubule biorientation, activation of the spindle assembly checkpoint and cytokinesis in association with phosphorylation of histone H3 on Ser 10.
1,3 Aurora C is specifically expressed in the testis and has a role in spermatogenesis. 4 Recent studies found that Aurora C also acted as a chromosomal passenger protein and might compensate for Aurora B function. 5 Several studies found that Aurora A and B were overexpressed in a variety of solid tumors, including colon, 6, 7 breast, [7] [8] [9] [10] prostate, 11 pancreas, 12 thyroid, 13 and head and neck cancers. 14 We have shown recently that hematological malignant cells including those from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), as well as chronic myeloid leukemia aberrantly expressed Aurora A and B kinases. 15 In addition, we have shown that ZM447439, a novel and selective inhibitor of Aurora A and B kinases, effectively induced growth arrest and apoptosis of a variety of types of leukemia cells. 15 Studies conducted by other groups noted that the phenotype of HeLa cells after their exposure to ZM447439 was similar to that induced by knock down of the Aurora B kinase gene. 16 We, therefore, hypothesized that Aurora B might be a more favorable molecular target for cancer therapy than Aurora A.
AZD1152 is a novel acetanilide-substituted pyrazole-aminoquinazoline prodrug that is converted rapidly to the active drug, AZD1152 hydroxy-QPA (AZD1152-HQPA), in human plasma. 17 AZD1152-HQPA is a specific inhibitor of the enzymatic activity of Aurora kinase, with selectivity for Aurora B (IC50 of 0.36 nM versus 1369 nM for Aurora B and A kinases, respectively); the inhibitor had less activity against a panel of more than 50-fold against other serine-threonine and tyrosine kinases including FLT3, JAK2 and Abl. 17, 18 AZD1152 was active against a variety of solid tumors as well as hematological malignant cells. c-Jun NH2-terminal kinase (JNK; also known as stressactivated protein kinase) is one of the mitogen-activated protein kinase superfamily. 20 JNK is known to be activated in response to certain growth factors, as well as environmental stresses such as ultraviolet radiation. Activated JNK mediates both apoptotic and prosurvival signal pathways. For example, 12-O-tetradecanoyl phorbol 13-acetate-induced phosphorylation of JNK, resulting in apoptosis of androgen-dependent human prostate cancer cells. 21 On the other hand, activation of JNK was required for interleukin-3-dependent proliferation of Ba/F3 murine pre-B cells. 22 In addition, JNK was shown to be required for survival and proliferation of B-lymphoma cells. 23 This study analyzed the expression of Aurora B in various types of non-Hodgkin lymphoma (NHLs) by immunohistochemistry and found that this kinase was highly expressed in histologically aggressive types of lymphoma such as diffuse large B cell (DLBC) and Burkitt lymphoma (BL). Inhibition of Aurora B by AZD1152 caused apoptosis of these cells in parallel with activation of the caspase pathway. In addition, AZD1152 synergistically enhanced the ability of vincristine (VCR), a tubulin-depolymerizing agent, to induce apoptosis of BL cells. Moreover, we found that VCR induced activation of Aurora kinases through stimulation of JNK, which was blocked by AZD1152 in BL cells.
MATERIALS AND METHODS Immunohistochemistry
A total of 71 paraffin-embedded malignant lymphoma samples were obtained by the Laboratory of Diagnostic Pathology of Kochi University Hospital during the period from 1992 to 2008. All specimens were obtained at the initial presentation of the patients. Patients' ages ranged from 23 to 95 years with a mean age of 65 years. Histology of malignant lymphoma was diagnosed according to the WHO classification by at least two experienced pathologists (TT and MF). This study included DLBC lymphoma (DLBCL, 21 cases), BL (7 cases), follicular lymphoma (FL, 13 cases), mantle cell lymphoma (MCL, 4 cases), mucosa-associated lymphoid tissue lymphoma (MALT, 3 cases), adult T-cell leukemia/ lymphoma (11 cases), peripheral T-cell lymphoma (9 cases), and Hodgkin lymphoma (3 cases). In total, 3 (two DLBCL and one MCL) out of 48 patients with B-cell lymphoma were diagnosed before 2001, and were treated with CHOP (cyclophosphamide, adriamycin, VCR and prednisone). Rest of the patients were treated with retuximab in combination with anti-cancer agents. The immunohistochemical procedure was performed with a Ventana DISCOVERY autostainer system according to the protocol provided by the manufacturer (Ventana Japan, Osaka, Japan). The anti-Aurora B antibody (EP1009Y, Epitomics, Burlingame, CA, USA) was used. The tissue sections were counterstained with hematoxylin and semiquantitatively scored as weakly positive ( þ ; 45 to 20%), moderately positive ( þ þ ; 420 to 80%) or markedly positive ( þ þ þ ; 480%).
The study was approved by the Ethics Committee of Kochi University (approved #20-54), and complied with the Helsinki Declaration.
Cells
Burkitt lymphoma/leukemia cell lines, BALM14, À18 and À27 were kind gifts from Dr A Hrashima (Hayashibara Biochemical Laboratories, Okayama, Japan). Daudi and Ramos Burkitt lymphoma cell lines were obtained from RIKEN BRC Cell Bank (Tsukuba, Japan). Acute promyelocytic leukemia NB4 and AML MOLM-13 cell lines were a kind gift from Dr M Lanotte (St Louis Hospital, Paris, France) and Dr Y Matsuo (Fujisaki Cell Center, Hayashibara Biochemical Laboratories), respectively. Bone marrow mononuclear cells and peripheral blood lymphocytes were isolated from healthy volunteers after obtaining informed consent, as previously described.
24
Reagents AZD1152-HQPA was provided by AstraZeneca (Macclesfield, UK). AZD1152-HQPA was dissolved in 100% dimethyl sulfoxide (DMSO; Burdick & Jackson, Muskegon, MI, USA) to a stock concentration of 10 mM and stored at À801C. The pan-caspase inhibitor z-Val-Ala-Asp (OMe)-Fluoromethylketone (z-VAD-FMK) and the JNK inhibitor SP600125 were purchased from BIOMOL International (Plymouth Meeting, PA, USA) and Calbiochem (San Diego, CA, USA), respectively, and were dissolved in 100% DMSO to a stock concentration of 20 mM.
3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assays Cells (5 Â 10 5 per ml) were cultured with various concentrations of AZD1152-HQPA for 2 days in 96-well plates. After culture, MTT assay was performed as previously described. 25 All experiments were performed in triplicate and repeated at least thrice.
Measurement of p-Histone H3 at Ser10 and P-JNK by Flow Cytometry
The Alexa Fluor 488-conjugated anti-p-histone H3 (Ser10, Cell Signaling Technology, Beverly, MA, USA) and antip-JNK (SC-6254, Santa Cruz, Santa Cruz, CA, USA) antibodies were used to quantify the population of leukemia/ lymphoma cells expressing the phosphorylated forms of histone H3 and JNK, respectively. These experiments were performed using flow cytometry.
Immunoblotting
Immunoblotting was performed as previously described. 26 The antibodies used were anti-PARP (Cell Signaling Technology), anti-caspase 3 (Cell Signaling Technology), anti-GAPDH (Abcam Japan, Tokyo, Japan), anti-Aurora B kinase (Cell Signaling Technology) and anti-p-Aurora A/B/C kinases (Cell Signaling Technology). Band intensities were measured by densitometry.
Small interfering RNA Control siRNA and a siRNA against JNK were purchased from Sigma (St Louis, MO, USA). Control siRNA targets green fluorescence proteins.
Transfections NB4 cells were transiently transfected with either control or JNK siRNA by Amaxa electroporator Nucleofector II (Wako Pure Chemical Industries, Osaka, Japan), using the Nucleofector Kit V (program X-001). The preliminary experiments using the green fluorescence protein-expressing vector found that efficacy of transfection with this program was approximately 70%, with approximately 80% cell viability, as measured by FACS and annexin V staining (data not shown). We used NB4 cells for these studies, because none of BL/leukemia cell lines were suitable for transfection (data not shown). We previously showed that NB4 cells expressed Aurora kinases and the inhibitor of these kinases effectively inhibited their proliferation. 15 
Data analysis
The w 2 -test was used to examine the relation between levels of Aurora B and clinical factors. The combination index (CI) for growth inhibition elicited by AZD1152-HPQA and VCR in leukemia cells was calculated using the median effect method of Chou and Talalay 27 (Calcusyn Software available from Biosoft, Cambridge, United Kingdom). CI values o1 indicate synergy, a CI ¼ 1 shows an additive effect and a CI 41 shows antagonism between the two agents. (Figure 1b) and none of them, except for one case of FL, highly expressed this protein kinase, suggesting that expression of Aurora B correlated with histological grade in B-cell NHLs (Po0.01). In addition, levels of Aurora B correlated with advanced clinical stage (P ¼ 0.024) and high International Prognostic Index (IPI) score (Po0.01) ( Table 1) .
Inhibition of Aurora B by AZD1152-HQPA Induced Growth Arrest and Apoptosis of BL/Leukemia Cells
We examined whether Aurora B could be a molecular target for the treatment of NHLs using BL/leukemia cells. Ramos, Daudi, BALM-14, À18 and À27 BL/leukemia cells expressed Aurora B protein as measured by western blot analysis (Figure 2a ). On the other hand, bone marrow mononuclear cells as well as peripheral blood lymphocytes from healthy volunteers did not express this kinase protein (Figure 2a) . Ph-positive B-ALL PALL-2 and AML MOLM-13 cells were used as a positive control. Exposure of BL/leukemia cells to various concentrations of AZD1152-HQPA (12.5-100 nM) for 2 days effectively inhibited their proliferation with IC50s between 50 and 100 nM, as measured by MTT assay ( Figure  2b ). As expected, AZD1152-HQPA (12.5-100 nM) did not affect the viability of peripheral blood lymphocytes from healthy volunteers (Figure 2b) .
Western blot analysis found that exposure of Ramos, BALM-14 and -27 cells to AZD1152-HQPA (12.5-100 nM) for 2 days increased levels of the cleaved forms of PARP and caspase 3, suggesting that AZD1152-HQPA induced apoptosis of these cells (Figure 2c ). Cleavage of PARP in Daudi cells was not associated with activation of caspase 3 ( Figure  2c ). Other caspases such as caspase 7 or 2 could cleave PARP, leading to the apotosis of Daudi cells. Pre-incubation of Ramos and BALM-27 cells with the pan-caspase inhibitor Z-VAD-FMS (50 mM, 1 h) blocked AZD1152-HQPA-induced cleavage of PARP and caspase 3; and AZD1152-HQPAmediated growth inhibition of these cells was blunted ( Figure  2d ). These observations suggested that AZD1152-HQPA-induced growth inhibition of BL/leukemia cells was, at least in part, caspase dependent.
AZD1152-HQPA Potentiated the Antiproliferative Activity of VCR Directed Against BALM-27 cells We examined the ability of AZD1152-HQPA to enhance the antiproliferative effects of the conventional anti-lymphoma/ leukemia agent, VCR. BALM-27 cells were cultured with various concentrations of AZD1152-HQPA (15-100 nM) and/or VCR (0.625-5 nM) for 48 h; and proliferation was measured by MTT assay (Figure 3a) . AZD1152-HQPA (30 nM) or VCR (2.5 nM) alone inhibited MTT activity by approximately 25 and 30%, respectively (Figure 3a) . When cells were exposed to both compounds in combination, proliferation was inhibited by approximately 80% (Figure 3a) , resulting in a CI value of o1 (synergistic antiproliferative effect, figure not shown).
VCR Activated Aurora Kinases
We next attempted to verify the molecular mechanisms by which inhibition of Aurora B potentiated the effects of VCR in BALM-27 cells. Exposure of BALM-27 cells to various concentrations of VCR (1.25-5 nM, 24 h) induced phosphorylation of Aurora kinase and its substrate p-Histone H3 in a dose-dependent manner, which were effectively blocked in the presence of AZD1152-HQPA (25 nM), as measured by FACS (Figures 3b,c) . Western blot analysis confirmed that VCR (1.25-5 nM, 24 h) stimulated the phosphorylation of Aurora kinases A and B in a dose-dependent manner, and (Figure 3d ).
JNK Mediated VCR-Stimulated Phosphorylation of Aurora Kinases
Further experiments explored the signal pathways, which mediated VCR-induced phosphorylation of Aurora kinases. was significantly (Po0.01) attenuated when JNK was downregulated in these cells (Figure 5b ).
Discussion
This study, for the first time, showed that Aurora B was aberrantly expressed in histologically high-grade NHLs such as DLBCLs and BLs ( Figure 1 , Table 1 ). In addition, we found that levels of Aurora B correlated with advanced clinical stage as well as high IPI scores ( Table 1) . Levels of Aurora B might be associated with a poor prognosis. z-VAD-FMK partially restored the AZD1152-HQPA-mediated growth inhibition of BL cells (Figure 2d ). These observations suggest that the AZD1152-HQPA-induced growth arrest of BL cells was mediated in both a caspase-dependent and -independent manner. Further studies are required to clarify the molecular mechanisms by which blockade of Aurora B kinase induces growth inhibition and apoptosis of BL cells. This study found that AZD1152-HQPA potentiated the ability of VCR to arrest the growth of BL cells. This finding was consistent with our previous studies, showing that AZD1152-HQPA synergized with VCR to inhibit the growth of MOLM13 AML and PALL-2 Ph þ ALL cells. 18 This study explored the molecular mechanisms, which produced synergistic growth inhibition of BALM-27 cells after exposure to combination of VCR and AZD1152. Exposure of these cells to VCR increased the levels of total, as well as the phosphorylated forms of Aurora B associated with the activation of JNK. Inhibition of JNK by the specific inhibitor SP600125 or the siRNA blocked VCR-stimulated phosphorylation of Aurora B, suggesting the involvement of JNK in VCR-induced activation of Aurora B kinase. Notably, when JNK was repressed by a siRNA, synergistic growth inhibition mediated by combination of VCR and AZD1152 was significantly attenuated ( Figure 5 ). VCRstimulated Aurora B through JNK signaling may have sensitized the cells to Aurora B kinase inhibition by AZD1152-HQPA. This may be the mechanism by which the combination of VCR and AZD1152-HQPA synergizes to inhibit the growth of BALM-27 cells.
Another group has shown Aurora A to be aberrantly expressed in high-grade lymphoma at the mRNA level. 28 In addition, these investigators found that the downregulation of Aurora A by antisense oligonucleotides slowed the proliferation of lymphoma cells both in vitro and in vivo, 28 indicating that Aurora A may be a promising molecular target for treatment of NHLs.
Polo-like kinase 1 (PLK1) is also recognized as a mitotic kinase and has an important role in various events in mitosis, including chromosome alignment and segregation, and cytokinesis. 29 PLK1 was aberrantly expressed in DLBCLs in association with high levels of Ki-67, a marker of proliferation, and its levels were correlated with high IPI scores and poor prognosis. 30, 31 We have recently found that BL/leukemia cells highly expressed PLK1 and inhibition of this kinae by a specific inhibitor or a siRNA induced growth arrest and apoptosis of these cells. 32 A variety of mitotic kinases may be disregulated in high-grade NHLs, and each of them can be a therapeutic target.
Both Aurora A and B kinases seem to be attractive molecular targets for the treatment of individuals with solid tumors as well as hematological malignancies. A number of small-molecule inhibitors with selectivity against Aurora A and/or Aurora B have been developed, including AZD1152 (a potent and selective inhibitor of Aurora B), MLN8054 33 (an orally available selective inhibitor of Aurora A), together with MK-0457, 34 and PHA-739358 35 (a pan-Aurora kinase inhibitor). These inhibitors are undergoing evaluation in clinical trials.
Taken together, our data indicate that Aurora B kinase may be a promising molecular target for individuals with highgrade lymphoma. Combined administration of AZD1152 and other chemotherapeutic agents such as VCR, should be further investigated in the clinical setting.
